Markets:

Overview

News

Currencies

International

Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

33.08 -1.30 (-3.78%)

Streaming Delayed Price Updated: 11:24 AM EST, Mar 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗

Today 7:39 EST

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.

Via Stocktwits

Topics Artificial Intelligence

Liquidia Corp (NASDAQ:LQDA) Reports Q4 2025 Profitability and Revenue Beat Driven by YUTREPIA Launch ↗

Today 7:24 EST

Via Chartmill

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Today 6:30 EST

From Liquidia Technologies, Inc.

Via GlobeNewswire

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Liquidia Corp (NASDAQ:LQDA) Identified as High-Growth Momentum Candidate by Minervini Trend Template ↗

February 03, 2026

Via Chartmill

LIQUIDIA CORP (NASDAQ:LQDA) Emerges as a High-Growth Momentum and Trend Template Candidate ↗

January 02, 2026

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

What's Next: Liquidia's Earnings Preview ↗

October 31, 2025

Via Benzinga

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

Via The Motley Fool

Topics Regulatory Compliance

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

February 26, 2026

United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company...

Via Finterra

Topics Earnings Economy Intellectual Property

United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’

February 26, 2026

As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026

February 26, 2026

From Liquidia Technologies, Inc.

Via GlobeNewswire

Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress

January 27, 2026

From Liquidia Technologies, Inc.

Via GlobeNewswire

Why Liquidia Stock Rocked the Market Today ↗

January 09, 2026

The company is clearly benefiting from the solid momentum of its newest drug on the market.

Via The Motley Fool

Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update

January 09, 2026

From Liquidia Technologies, Inc.

Via GlobeNewswire

Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Liquidia Technologies, Inc.

Via GlobeNewswire

Liquidia Corp (NASDAQ:LQDA) Emerges as a High-Growth Momentum Leader ↗

December 12, 2025

Liquidia Corp (LQDA) exemplifies a high-growth momentum stock in a strong technical uptrend, combining surging revenue with a top-rated chart pattern.

Via Chartmill

One Fund Just Dumped $13 Million in This Offshore Drilling Stock — Here's What Long-Term Investors Should Know ↗

November 27, 2025

One fund just walked away from a rising offshore driller—here’s what long-term investors should make of the move.

Via The Motley Fool

This Small-Cap Consumer Stock Has Landed New Institutional Backing as Shares Surge 60% ↗

November 27, 2025

A fast-growing niche segment may be the real reason this small-cap consumer products stock is drawing new institutional attention.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys ↗

November 27, 2025

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Liquidia Corp (LQDA) Stock: A High-Growth Pick Meeting the Minervini Trend Template ↗

November 15, 2025

Liquidia (LQDA) stock shows a powerful technical uptrend and explosive 1,121% revenue growth, aligning with the high-momentum Minervini strategy.

Via Chartmill

Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday ↗

November 04, 2025

Via Benzinga

Expert Outlook: Liquidia Through The Eyes Of 7 Analysts ↗

November 04, 2025

Via Benzinga

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

November 03, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

Liquidia Corp (NASDAQ:LQDA) Smashes Q3 2025 Estimates with Stellar YUTREPIA Launch ↗

November 03, 2025

Liquidia's Q3 2025 results crushed expectations with $54.3M revenue, driven by the successful launch of YUTREPIA. The stock surged as the company moves toward profitability.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 03, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗

October 30, 2025

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Via Investor's Business Daily

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

October 27, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.